RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cell therapy trial offers hope for patients with aggressive blood cancers
Disease control Recruiting nowThis early-phase study is testing a new type of cell therapy called CT0596 CAR-T in patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to bette…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Experimental 'Off-the-Shelf' cell therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy called CB-011 for people with multiple myeloma that has returned or stopped responding to standard treatments. Researchers will give participants modified immune cells designed to target and fight the cancer, then monit…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New cell therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called IMV102 in patients with multiple myeloma that has returned or stopped responding to other treatments. The research will check if the treatment is safe and if it helps control the cancer. About 30 patients who have alread…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope for Tough-to-Treat blood cancer: trial tests drug combos
Disease control Recruiting nowThis study is testing a new drug called sonrotoclax for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers want to see if sonrotoclax is safe and effective when given alone or combined with other standard myeloma drugs. The tria…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new drug called LBL-034 in people with multiple myeloma that has returned or isn't responding to other treatments. The first part aims to find a safe and tolerable dose. The second part will see how well the drug works at shrinking the cancer and keeping i…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Breakthrough cell therapy trial offers hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether a new, advanced cell therapy called AZD0120 works better than current standard drug combinations for people with multiple myeloma that has come back after treatment. The therapy involves modifying a patient's own immune cells to attack two sp…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for Tough-to-Treat blood cancer: first human trial begins
Disease control Recruiting nowThis is the first study in people testing a new drug called ISB 2001 for multiple myeloma that has returned or stopped responding to all standard treatments. Researchers will give increasing doses to about 200 participants to find a safe amount and see if it helps control the can…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Ichnos Sciences SA • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New combo therapy tested for advanced blood cancer
Disease control Recruiting nowThis study is testing if a combination of two drugs, elranatamab and isatuximab, can help control multiple myeloma that has returned or stopped responding to other treatments. It will enroll 30 adults whose cancer has progressed after at least two prior therapies. The goal is to …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New drug combo tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether a new drug called cemsidomide, when given with a standard steroid (dexamethasone), can help control multiple myeloma that has come back or stopped responding to other treatments. It is for adults who have already tried at least three different types …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Feb 27, 2026 15:05 UTC
-
Researchers track Real-Life results for Tough-to-Treat blood cancer
Knowledge-focused Recruiting nowThis study aims to observe and document how standard treatments for relapsed multiple myeloma perform in real-world clinical practice, not in a controlled trial. It will follow 300 patients who have already tried several other treatments, tracking how well the treatments work, th…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC